Figure 1. Mechanisms of ALK inhibitor resistance and therapeutic strategies. (Top) Pie charts indicating frequencies of mechanisms of resistance to 1st (crizotinib) and 2nd generation (ceritinib or alectinib) ALK TKIs, modified from reference [7]. (Bottom) Flow chart of currently approved ALK TKIs, mechanisms of resistance, sequence of therapeutic targeting and possible avenues for clinical development of novel strategies.
![Figure 1. Mechanisms of ALK inhibitor resistance and therapeutic strategies. (Top) Pie charts indicating frequencies of mechanisms of resistance to 1st (crizotinib) and 2nd generation (ceritinib or alectinib) ALK TKIs, modified from reference [7]. (Bottom) Flow chart of currently approved ALK TKIs, mechanisms of resistance, sequence of therapeutic targeting and possible avenues for clinical development of novel strategies.](/cms/asset/1d6295e6-27f4-4516-aede-d080b101837f/kccy_a_1247568_f0001_c.gif)
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
